warnings
WARNINGS: For external use only. Not for ophthalmic use.
Bruselix Cream
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Bruselix Cream
- Generic name
- LIDOCAINE HCI 3.88%
- Manufacturer
- PureTek Corporation
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 1510163f-b7fd-2e17-e063-6394a90a1799
- SPL ID
- 155cde19-44b5-545a-e063-6294a90aeaeb
- Version
- 2
- Effective date
- 2024-04-05
- Source export date
- 2026-09-28
- Source partition
- 3
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0003-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-09-28/fd09911bd1bc81f7f2faeb048e63855fe224e494376ae919a0035190e315c050/drug-label-0003-of-0014.json.zip
- Source manifest SHA-256
- cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
- Import run
- 20260929T050834Z
- Imported at
- 2026-09-29 05:17:50
| Harmonized routes |
|---|
| TOPICAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| brand name | Bruselix Cream | openfda.brand_name | |
| generic name | LIDOCAINE HCI 3.88% | openfda.generic_name | |
| manufacturer name | PureTek Corporation | openfda.manufacturer_name | |
| ndc | package | 59088-234-05 | openfda.package_ndc |
| ndc | product | 59088-234 | openfda.product_ndc |
| ndc11 | package | 59088023405 | derived:openfda.package_ndc |
| rxcui | 2678114 | openfda.rxcui | |
| rxcui | 1723991 | openfda.rxcui | |
| spl id | 155cde19-44b5-545a-e063-6294a90aeaeb | id | |
| spl set id | 1510163f-b7fd-2e17-e063-6394a90a1799 | set_id | |
| unii | V13007Z41A | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS: During or immediately after treatment, the skin at the site of treatment may develop erythema or edema or may be the locus of abnormal sensation.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.